PT  - JOURNAL ARTICLE
AU  - Jacques L Tamuzi
AU  - Gomer Lulendo
AU  - Patrick Mbuesse
AU  - Peter S. Nyasulu
TI  - The incidence and mortality of COVID-19 related TB disease in Sub-Saharan Africa: A systematic review and meta-analysis
AID  - 10.1101/2022.01.11.22269065
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.01.11.22269065
4099  - http://medrxiv.org/content/early/2023/01/10/2022.01.11.22269065.short
4100  - http://medrxiv.org/content/early/2023/01/10/2022.01.11.22269065.full
AB  - Background Coronavirus disease 2019 (COVID-19) is also associated with other co-morbidities in people who have previously or currently have pulmonary tuberculosis (PTB). PTB is a risk factor for COVID-19, both in terms of severity and mortality, regardless of HIV status. However, there is less information available on COVID-19 and PTB in terms of incidence and mortality rates in Sub-Saharan Africa (SSA), a high-burden TB region. This systematic review provided a data synthesis of available evidence on COVID-19/PTB incidence and case fatality rates, as well as mortality rates found in clinical and post-mortem COVID-19/PTB diagnostics in SSA.Methods We conducted an electronic search in the PubMed, Medline, Google Scholar, Medrxix, and COVID-19 Global literature on coronavirus disease databases for studies involving COVID-19 and PTB in Sub-Saharan Africa. The primary outcomes were the incidence proportion of people with COVID-19 who had current or previous PTB, as well as the case fatality rate associated with COVID-19/PTB. Based on methodological similarities in the included random effect model studies, the combination method was developed using Stata version 16 and Prometa 3 software. We also performed sensitivity analysis and meta-regression.Results From the 548 references extracted by the literature search, 25 studies were selected and included in the meta-analysis with a total of 191, 250 COVID-19 infected patients and 11, 480 COVID-19 deaths. The pooled COVID-19/PTB incidence was 3% [2%-5%] and a case fatality rate of 13% [4%-23%]. The pooled estimates for case fatality rate among COVID-19/PTB were 7% [1%-12%] for clinical PTB diagnostic and 25% [3%-47%] for post-mortem PTB diagnostic. Previous TB had the highest incidence and fatality rates with 46 [19-73] per 1, 000 population and 8% [3%-19%], respectively. Meta-regression model including the effect sizes and cumulative COVID-19 cases (P= 0.032), HIV prevalence (P= 0.041), and TB incidence (P= 0.002) to explain high heterogeneity between studies.Conclusion To summarize, the incidence of TB associated with COVID-19 is higher in SSA, as are the case fatality rates, when compared to the rest of the world. However, because the post-mortem TB diagnostic was higher, COVID-19 associated with TB may have been underreported in studies conducted in SSA. To confirm COVID-19/TB incidence and case fatality rates in SSA, large-scale cohort studies that adequately clear tools on previous and/or current TB diagnostic tools are required.Review registration PROSPERO (CRD42021233387)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42021233387Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data are openly available: PubMed, Medline, Google Scholar, Medrxix and COVID-19 Global literature on coronavirus disease databasesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsACE2Angiotensin-Converting Enzyme 2ARDSAcute respiratory distress syndromeCOVID-19Coronavirus disease 2019HIVhuman immunodeficiency virusLC-ILDlong COVID-19-related interstitial lung diseaseMCP-1Monocyte Chemoattractant Protein-1mRNAmessenger RNANOSNewcastle-Ottawa scalePCPFpost-COVID pulmonary fibrosisPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesPTBpulmonary tuberculosisSSAsub-Saharan AfricaSARS-CoV-2Severe acute respiratory syndrome coronavirus 2TBtuberculosisTGF-βtransforming growth factorWHOWorld Health Organization